Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation (IART) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
iart · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Integra LifeSciences Holdings Corporation (IART) measures how much investors pay for each dollar of the company's trailing earnings. IART's current PE ratio of N/A is calculated by dividing its stock price of $17.04 by its TTM earnings per share of -$6.44.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 16 fiscal years · Front-end computedMinQ1 · 25%37.9x
MedianQ3 · 75%99.4x
Max
At N/A, IART's current P/E is lower than in 0% of its annual fiscal year readings over the past 16 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Integra LifeSciences Holdings CorporationYou IART | $1.3B | N/A | — | -$6.44 |
 Bicara Therapeutics Inc. Common Stock BCAX | $1.1B | N/A | — | -$2.52 |
 Butterfly Network, Inc. BFLY | $1.2B | N/A | — | -$0.31 |
 EyePoint Pharmaceuticals, Inc. EYPT | $968M | N/A | — | -$3.17 |
 Fortrea Holdings Inc. FTRE | $1.6B | N/A | — | -$10.81 |
 InMode Ltd. INMD | $824M | 10.12x | — | $1.45 |
 Maravai LifeSciences Holdings, Inc. MRVI | $1.4B | N/A | — | -$0.90 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-6.73 | — | |
2024-12-31 FY2024 | — | $-0.09 | — | |
2023-12-31 FY2023 | 50.25x | $0.87 | +95.0% | |
2022-12-31 FY2022 | 25.77x | $2.18 | -23.2% | |
2021-12-31 FY2021 | 33.56x | $2.00 | -18.2% | |
2020-12-31 FY2020 | 41.04x | $1.58 | -58.7% | |
2019-12-31 FY2019 | 99.42x | $0.59 | +61.8% | |
2018-12-31 FY2018 | 61.46x | $0.73 | +6.1% | |
2017-12-31 FY2017 | 57.95x | $0.83 | +34.8% | |
2016-12-31 FY2016 | 42.98x | $1.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Integra LifeSciences Holdings Corporation (IART) measures how much investors pay for each dollar of the company's trailing earnings. IART's current PE ratio of N/A is calculated by dividing its stock price of $17.04 by its TTM earnings per share of -$6.44.
Frequently asked questions
IART pe ratio · 6 questionsIART's current PE ratio is N/A as of 2026-06-08, based on a stock price of $17.04 and TTM EPS of -$6.44. Data sourced from Financial Modeling Prep via IART's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Integra LifeSciences Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08